Company Profile

Aslan Pharmaceuticals Limited (NASDAQ: ASLN)
5:00 PM UTC, 07/03/24
Last: $2.38 Change: +0.13 %Change: +5.87% Volume: 56,823
Detailed Quote
Open: $ 2.20   Volume: 56,823
High: $ 2.53   Yield(%) 0.00
Low: $ 2.20   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 6.34M
EPS ($) -1.99   Shares Out: 22.63M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -38.12
% Price Change (last 13 weeks): -50.70
% Price Change (last 26 weeks): -48.91
% Price Change (last 52 weeks): -92.28
% Price Change (year to date): -93.30
Management Effectiveness
Return on Equity (%): n/a
Return on Assets (%): -103.06
Return on Invested Capital (%): -127.94
Profitability
Gross Profit Margin (%): 97.10
Net Profit Margin (%): -368.50
Operating Profit Margin (%): -364.46
Price & Volume
50-day Moving Average: $3.28
200-day Moving Average: $5.90
Avg. Daily Vol. (last 50 days): 59,802
Avg. Daily Vol. (last 200 days): 61,110
52-wk high: $31.12
52-wk low: $2.17
Bid: $2.27
Ask: $2.45
Company Information
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which develops novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.
Aslan Pharmaceuticals Limited
3 Temasek Avenue 18 Level Centennial Tower
Singapore CE 039190

Phone: 65.6817.9598
Fax: n/a
http://www.aslanpharma.com
Per Share Data
Earnings (1year) ($): -1.99
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): -0.76
Cash Flow ($): -2.49
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 0.72
Price/Book (x): n/a
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 1.84
Current Ratio (x): 1.84
LT Debt/Equity (x): n/a
Total Debt/Equity (x): n/a



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.